ATE245142T1 - No-synthase inhibitoren - Google Patents

No-synthase inhibitoren

Info

Publication number
ATE245142T1
ATE245142T1 AT99926397T AT99926397T ATE245142T1 AT E245142 T1 ATE245142 T1 AT E245142T1 AT 99926397 T AT99926397 T AT 99926397T AT 99926397 T AT99926397 T AT 99926397T AT E245142 T1 ATE245142 T1 AT E245142T1
Authority
AT
Austria
Prior art keywords
synthase inhibitors
synthase
inhibitors
Prior art date
Application number
AT99926397T
Other languages
English (en)
Inventor
Paul John Beswick
Savvas Kleanthous
Robert John Young
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE245142T1 publication Critical patent/ATE245142T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99926397T 1998-05-30 1999-05-27 No-synthase inhibitoren ATE245142T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811599.1A GB9811599D0 (en) 1998-05-30 1998-05-30 Nitric oxide synthase inhibitors
PCT/EP1999/003583 WO1999062875A1 (en) 1998-05-30 1999-05-27 Nitric oxide synthase inhibitors

Publications (1)

Publication Number Publication Date
ATE245142T1 true ATE245142T1 (de) 2003-08-15

Family

ID=10832929

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926397T ATE245142T1 (de) 1998-05-30 1999-05-27 No-synthase inhibitoren

Country Status (30)

Country Link
US (2) US6355689B1 (de)
EP (1) EP1084104B1 (de)
JP (1) JP3839256B2 (de)
KR (1) KR20010043920A (de)
CN (1) CN1218940C (de)
AP (1) AP1382A (de)
AT (1) ATE245142T1 (de)
AU (1) AU757042B2 (de)
BR (1) BR9910849A (de)
CA (1) CA2333322C (de)
CZ (1) CZ297473B6 (de)
DE (1) DE69909625T2 (de)
DK (1) DK1084104T3 (de)
EA (1) EA003026B1 (de)
EE (1) EE04149B1 (de)
ES (1) ES2203147T3 (de)
GB (1) GB9811599D0 (de)
HU (1) HUP0102472A3 (de)
ID (1) ID26790A (de)
IL (1) IL139697A (de)
IS (1) IS2442B (de)
NO (1) NO20006044L (de)
NZ (1) NZ508222A (de)
PL (1) PL194784B1 (de)
PT (1) PT1084104E (de)
RS (1) RS49984B (de)
SK (1) SK18052000A3 (de)
TR (1) TR200003539T2 (de)
WO (1) WO1999062875A1 (de)
ZA (1) ZA200006847B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1265859T3 (da) 2000-03-24 2006-05-01 Pharmacia Corp Amidinoforbindelser der er nyttige som nitrogenoxidsyntaseinhibitorer
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
JPWO2003022309A1 (ja) * 2001-09-10 2004-12-24 小野薬品工業株式会社 アレルギー疾患治療剤
US20030109522A1 (en) * 2001-09-24 2003-06-12 Manning Pamela T. Ophthalmologic treatment methods using selective iNOS inhibitors
EP1505972A2 (de) * 2002-05-16 2005-02-16 Pharmacia Corporation Ein selektiver inos-inhibitor in kombination mit einem pde-inhibitor zur behandlung von respiratorischen erkrankungen
CN1652843A (zh) * 2002-05-16 2005-08-10 法玛西雅公司 使用选择性iNOS抑制剂治疗呼吸系统疾病和病症
CA2494284A1 (en) * 2002-08-02 2004-02-12 Pharmacia Corporation Methods for treatment and prevention of gastrointestinal conditions
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316212D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Novel compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US20050203082A1 (en) * 2003-08-13 2005-09-15 Hsu Chung Y. Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
EP1841780B1 (de) 2005-01-10 2011-07-27 Glaxo Group Limited Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
WO2007000884A1 (ja) * 2005-06-29 2007-01-04 National University Corporation Kanazawa University 骨・関節疾患の予防・治療剤およびそのスクリーニング方法
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
SI2046787T1 (sl) 2006-08-01 2011-07-29 Glaxo Group Ltd Pirazolo(3,4-b)piridinske spojine in njihova uporaba kot PDE4 inhibitorji
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP2408917A2 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von bach1 (btb and cnc homology 1, basic leucine zipper transcription factor 1) unter verwendung von sina (short interfering nucleic acid)
EP2408915A2 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von gata-bindungsprotein 3 (gata3) unter verwendung von sina (short interfering nucleic acid)
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408458A1 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-schnittstellen-vermittelte unterdrückung der signal transducer and activator of transcription 6 (stat6) genexpression mit short interfering nucleic acid (sina)
AU2010229847A1 (en) 2009-03-27 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
WO2010125082A1 (en) 2009-04-30 2010-11-04 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
EP2507226A1 (de) 2009-12-03 2012-10-10 Glaxo Group Limited Neuartige verbindungen
EP2507231A1 (de) 2009-12-03 2012-10-10 Glaxo Group Limited Indazolderivate als pi3-kinaseinhibitoren
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
EP2512438B1 (de) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulierungen und verfahren zur steuerung der mdi-partikelgrössenfreisetzung
TWI375671B (en) * 2010-03-01 2012-11-01 Univ China Medical Pharmaceutical compositions containing brazilin for inhibiting expression of cytokines of t helper cell type ii and/or inhibiting expression of chemokines and uses of the same
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
RS54286B1 (sr) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
MX2016012574A (es) 2014-03-28 2017-09-26 Calitor Sciences Llc Compuestos heteroarilo sustituidos y metodos de uso.
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2049582A (en) 1931-11-04 1936-08-04 Rohm & Haas Amidines
US4085217A (en) 1964-01-29 1978-04-18 L'oreal Process and cosmetic compositions for the treatment of skin and scalp
US4085218A (en) 1975-10-30 1978-04-18 Sandoz Ltd. Elevating mood in geriatric patients
US4512979A (en) 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
DE3260831D1 (en) 1981-06-05 1984-10-31 Merck & Co Inc Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same
US4594341A (en) 1982-04-06 1986-06-10 Merck & Co., Inc. Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives as antihypertensives
FI832053L (fi) 1982-06-10 1983-12-11 Syntex Inc Nonapeptid- och dekapeptidanaloger av lhrh anvaendbara som lhrh-antagonister samt deras framstaellningsfoerfarande
DE3514450A1 (de) 1985-04-22 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von imidaten sowie neue arylsubstituierte imidate
US5028627A (en) 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
GB8929076D0 (en) 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation
CA2036770C (en) 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
DE4310202A1 (de) 1992-03-30 1993-10-07 Ciba Geigy µ-Ketoimidoester als Stabilisatoren für chlorhaltige Polymerisate
US5281627A (en) 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof
US5585402A (en) 1992-12-23 1996-12-17 Glaxo Wellcome Inc. Nitric oxide synthase inhibitors
US5364881A (en) 1993-11-15 1994-11-15 The Medical College Of Wisconsin Research Foundation, Inc. S-alkyl-isothioureido-amino acids and use thereof
EP0957087B1 (de) 1994-06-15 2002-12-04 The Wellcome Foundation Limited Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren
FR2727111B1 (fr) 1994-11-21 1997-01-17 Hoechst Lab Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.

Also Published As

Publication number Publication date
EP1084104A1 (de) 2001-03-21
ZA200006847B (en) 2001-11-22
HUP0102472A3 (en) 2002-12-28
JP2002516901A (ja) 2002-06-11
WO1999062875A1 (en) 1999-12-09
EE200000716A (et) 2002-04-15
JP3839256B2 (ja) 2006-11-01
DE69909625T2 (de) 2004-06-24
EA003026B1 (ru) 2002-12-26
DK1084104T3 (da) 2003-10-27
EE04149B1 (et) 2003-10-15
GB9811599D0 (en) 1998-07-29
HUP0102472A2 (hu) 2002-03-28
IL139697A (en) 2005-12-18
NO20006044L (no) 2001-01-29
RS49984B (sr) 2008-09-29
KR20010043920A (ko) 2001-05-25
PL344368A1 (en) 2001-11-05
YU74600A (sh) 2002-12-10
DE69909625D1 (en) 2003-08-21
PT1084104E (pt) 2003-11-28
NO20006044D0 (no) 2000-11-29
EP1084104B1 (de) 2003-07-16
SK18052000A3 (sk) 2001-06-11
ID26790A (id) 2001-02-08
CZ297473B6 (cs) 2006-12-13
IS5723A (is) 2000-11-21
AP2000001998A0 (en) 2000-12-31
CN1303367A (zh) 2001-07-11
TR200003539T2 (tr) 2001-06-21
ES2203147T3 (es) 2004-04-01
IL139697A0 (en) 2002-02-10
HK1034241A1 (en) 2001-10-19
CN1218940C (zh) 2005-09-14
CA2333322A1 (en) 1999-12-09
NZ508222A (en) 2003-02-28
BR9910849A (pt) 2001-02-20
CA2333322C (en) 2008-01-22
AU4367199A (en) 1999-12-20
PL194784B1 (pl) 2007-07-31
US6495606B1 (en) 2002-12-17
AP1382A (en) 2005-04-01
AU757042B2 (en) 2003-01-30
EA200001122A1 (ru) 2001-06-25
US6355689B1 (en) 2002-03-12
IS2442B (is) 2008-11-15
CZ20004450A3 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
ATE245142T1 (de) No-synthase inhibitoren
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
LTC1124961I2 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
ID28266A (id) Senyawa-senyawa amidin
PT1181017E (pt) Inibidores de metaloproteases
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
ATE460424T1 (de) Factor viia inhibitore
NO20011745L (no) Forbindelser
FI4209U1 (fi) Uusia yhdisteitä
PT1194404E (pt) Inibidores de aspartil-protease
NO20012960D0 (no) Farnesylproteintransferase-inhibitorer
NO20005006L (no) Kalsilytiske forbindelser
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20006662D0 (no) Fluorfenylresin-forbindelser
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
ID23196A (id) Gandaran untuk lampuflouresen
DE69930852D1 (de) Prenyltransferase-inhibitoren
SE9800626D0 (sv) Compounds
SE9800834D0 (sv) New Compounds
SE9800508D0 (sv) New Compounds
SE9800509D0 (sv) New Compounds
SE9803747D0 (sv) New compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1084104

Country of ref document: EP

REN Ceased due to non-payment of the annual fee